Research Topics
| I M HoldawaySummaryCountry: New Zealand Publications
| Collaborators
|
Detail Information
Publications
Excess mortality in acromegalyI M Holdaway
Department of Endocrinology, Greenlane Clinical Centre, Auckland City Hospital, Auckland, New Zealand
Horm Res 68:166-72. 2007....- A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegalyI M Holdaway
Department of Endocrinology, Greenlane Clinical Centre and Auckland City Hospital, PO Box 92189, Auckland 1142, New Zealand
Eur J Endocrinol 159:89-95. 2008..A meta-analysis of mortality studies in acromegaly has thus been performed to assess the effect of lowering serum GH and IGF-I on survival... - Long-term treatment outcome in acromegalyI M Holdaway
Department of Endocrinology, Auckland Hospital, Park Road, Auckland 1, New Zealand
Growth Horm IGF Res 13:185-92. 2003..Available data suggest that achieving similar growth hormone levels after treatment also reduces the prevalence of chronic complications of the disorder, which is subsequently reflected in improved mortality... - Factors influencing mortality in acromegalyIan M Holdaway
Department of Endocrinology, Auckland Hospital, Auckland 1, New Zealand
J Clin Endocrinol Metab 89:667-74. 2004..02), indicating that GH and IGF-I act equivalently as predictors of mortality. These findings indicate that reduction of GH to less than 1 microg/liter or normalization of serum IGF-I reduces mortality to expected levels... - Treatment of acromegalyIan M Holdaway
Department of Endocrinology, Auckland Hospital, Auckland, New Zealand
Horm Res 62:79-92. 2004..A primary surgical approach, followed by medical therapy for those not in remission, remains the preferred option in most centres... - Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancerIan M Holdaway
Departments of Endocrinology and Oncology, Auckland Hospital, Auckland, New Zealand
ANZ J Surg 73:905-8. 2003..IGF-I and IGFBP-3 have therefore been measured in women with advanced breast cancer to determine if changes in serum levels predict the response to treatment by chemotherapy... - Serum levels of insulin-like growth factor binding protein-3 in benign and malignant breast diseaseI M Holdaway
Department of Endocrinology, School of Medicine, Auckland University, New Zealand
Aust N Z J Surg 69:495-500. 1999..The present study investigates whether this pattern also occurs in neoplastic breast disease... - The relationship of urinary and plasma androgens to steroid receptors and menopausal status in breast cancer patients and their influence on survivalB H Mason
Department of Endocrinology, School of Medicine, Auckland, New Zealand
Breast Cancer Res Treat 32:203-12. 1994..Nonetheless, the identification of this subgroup of node negative breast cancer women with reduced survival may be important when considering node negative patients for adjuvant therapy... - Characteristics of the menstrual cycle at the time of surgery for breast cancerI M Holdaway
Department of Endocrinology, University of Auckland School of Medicine, New Zealand
Br J Cancer 75:413-6. 1997..The timing of surgery in the cycle did not influence the hormonal data. The hormonal characteristics of the menstrual cycle thus appear to be normally preserved in women during the month in which breast cancer surgery is performed... - Season of initial discovery of tumour as an independent variable predicting survival in breast cancerB H Mason
Department of Surgery, Auckland Hospital, New Zealand
Br J Cancer 61:137-41. 1990..This study suggests that the season of first detection of a breast cancer relates significantly to the later behaviour of the tumour, and may reflect seasonal changes in hormone dependent growth... - Seasonal changes in serum melatonin in women with previous breast cancerI M Holdaway
Department of Endocrinology, Auckland Hospital, New Zealand
Br J Cancer 64:149-53. 1991.... - Effect of breast surgery on serum levels of insulin-like growth factors (IGF-I, IGF-II, and IGF binding protein-3) in women with benign and malignant breast lesionsI M Holdaway
Department of Endocrinology, School of Medicine, Auckland University, New Zealand
Ann Surg Oncol 8:25-31. 2001..001). The fall in IGF-II was significantly related to the size of the removed tumor. CONCLUSIONS: Breast cancer may directly influence the serum concentration of IGF-II, possibly by direct tumor production... - Epidemiology of acromegalyI M Holdaway
Department of Endocrinology, Auckland Hospital, New Zealand
Pituitary 2:29-41. 1999..Overall, however, the most important prognostic variable appears to be the serum GH concentration achieved by treatment, with an increasing consensus that this needs to be < 2.5 ug/L (5 mU/L) to achieve cure of the condition... - Serum IGF-I levels are similar in Samoan, M?ori and European populations despite differences in body compositionW Bagg
Department of Medicine, University of Auckland, E com House, 3 Ferncroft Street, Grafton, Auckland, New Zealand
Growth Horm IGF Res 16:57-60. 2006..To determine if serum IGF-I concentrations are similar in healthy adult subjects from the Samoan, M?ori and European populations in New Zealand... - Melanocortin-3 receptor gene variants in a Maori kindred with obesity and early onset type 2 diabetesJencia Wong
Department of Medicine, University of Auckland, Auckland, New Zealand
Diabetes Res Clin Pract 58:61-71. 2002....